Luis Alberto Ramírez Islas

Mr. Luis Alberto Ramírez Islas

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Paul A. VallePaul A. Valle
Paul A. Valle
LCLuis N. Coria
Luis N. Coria
YSYolocuauhtli Salazar
Yolocuauhtli Salazar
CPCorina Plata
Corina Plata
LILuis Alberto Ramírez Islas
Luis Alberto Ramírez Islas
This work presents a mechanistic nonlinear model to explore the dynamics of Chronic Lymphocytic Leukemia (CLL) under combined chemoimmunotherapy with CAR-T cells and chlorambucil. The model, formulated by a set of three first-order Ordinary Differential Equations (ODEs), captures the short- and long-term effects of both therapies on the leukemia cells population. Utilizing a model-based design approach, we determine optimal dosing strategies through extensive in silico experimentation. Nonlinear system theories are applied to analyze the local and global dynamics of the system, allowing us to derive sufficient conditions for therapy dosing and treatment protocol design. Additionally, we compare dose-escalation and dose de-escalation protocols, illustrating the potential for complete eradication, partial response or relapse if therapies fail to completely eradicate cancer. Our results emphasize the utility of mathematical modeling in improving treatment strategies on the emerging field of personalized medicine.

10 April 2025 in Hemato
Verified
Journal Article
Open access
PDF file
Paul A. VallePaul A. Valle
Paul A. Valle
LCLuis N. Coria
Luis N. Coria
YSYolocuauhtli Salazar
Yolocuauhtli Salazar
CPCorina Plata
Corina Plata
LILuis Alberto Ramírez Islas
Luis Alberto Ramírez Islas
Background: This work presents a mechanistic nonlinear model, formulated as a system of first-order Ordinary Differential Equations, to investigate the dynamics of Chronic Lymphocytic Leukemia (CLL) under combined chemoimmunotherapy using CAR-T cells and chlorambucil. Methods: Leveraging nonlinear dynamical systems theory and a model-based design approach, we derive optimal dosing strategies through extensive in silico simulations, providing hemato-oncologists with actionable tools to refine CLL treatment. The model captures the short- and long-term impacts of both therapies on leukemia cell populations, enabling precise predictions of therapeutic outcomes. Results: By analyzing local and global system dynamics, we establish sufficient conditions for dosing and protocol design, offering a framework to optimize therapies based on individual patient responses. Comparisons of dose-escalation and -de-escalation strategies further demonstrate potential trajectories, such as complete eradication, partial response, or relapse, providing data-driven guidance for improving patient care. Conclusions: This study highlights the power of mathematical modeling in blood cancer research, enhancing the development of personalized and effective CLL treatment regimens.